covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Patrones de persistencia y recurrencia en sarcomas uterinos
Información de la revista
Vol. 46. Núm. 3.
Páginas 114-121 (enero 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 46. Núm. 3.
Páginas 114-121 (enero 2003)
Acceso a texto completo
Patrones de persistencia y recurrencia en sarcomas uterinos
Persistence and recurrence patterns of uterine sarcomas
Visitas
3907
J.A. De León Luisa,
Autor para correspondencia
jdeleonluis@hotmail.com

Correspondencia: Servicio de Obstetricia y Ginecología. IPOG. Hospital General Universitario Gregorio Marañón. Maiquez, 7. Planta D. 28007 Madrid. España
, M.P. Pintadoa, F. Vicandia, M.C. Carrascob, L. Chivaa, A. Ripolla, R. Mendizábala, E. Prietoa, J.A. Claveroa
a Servicio de Obstetricia y Ginecología. Hospital General Universitario Gregorio Marañón. Madrid. España
b Servicio de Anatomía Patológica. Hospital General Universitario Gregorio Marañón. Madrid. España
Este artículo ha recibido
Información del artículo
Resumen
Objetivo

Estudiar los patrones de persistencia y recurrencia que han tenido lugar en 48 casos de sarcomas uterinos diagnosticados en el Hospital General Universitario Gregorio Marañón entre 1992-2001.

Material y métodos

Del total de 48 pacientes, 25 fueron leiomiosarcomas, 18 carcinosarcomas, y 5 sarcomas del estroma endometrial. Se analizan las siguientes variables: edad, estado menopáusico, clínica, grado de mitosis, estadio quirúrgico, tratamientos primario y adyuvante, supervivencia, persistencia y recurrencia.

Resultados

Tras el tratamiento inicial, la enfermedad persiste en 11 de los pacientes (29%), de forma local (pelvis) (81,8%) y extrapelviana (19,2%). La enfermedad recurrió en 17 pacientes (35,41%) tras el tratamiento en la pelvis en un 51,9%. La supervivencia global de la enfermedad fue del 64,2% a los 2 años, del 51,25% a los 3 años y del 25,12% a los 5 años.

Conclusiones

En estos casos, la persistencia y la recurrencia suelen ser la norma, y la enfermedad presenta cierta heterogeneidad biológica, que se pone de manifiesto a la hora de analizar los distintos factores pronósticos. En general, la supervivencia es escasa y las estrategias terapéuticas actuales se encuentran en discusión.

Palabras clave:
Sarcomas uterinos
Persistencia
Recurrencia
Summary
Objective

We studied persistence and recurrence in 48 cases of uterine sarcoma diagnosed at the Gregorio Marañón University General Hospital from 1992-2001.

Material and methods

Of 48 cases of sarcoma, 25 were leiomyosarcomas, 18 were carcinosarcomas and 5 were endometrial stroma sarcomas. Age, menopause status, presenting symptoms, mitosis grade, surgical staging, primary treatment, adjuvant treatment, survival, recurrence, and persistence were analyzed.

Results

After initial treatment, persistence occurred in 11 patients (29%). Persistence was local (pelvic) in 81.8% and extra-pelvic in 19.2%. After treatment, recurrence occurred in 17 patients (35.41%) and localization was pelvic in 51.9%. Overall survival was 64.2 % at 2 years, 51.25% at 3 years and 25.12% at 5 years.

Conclusions

Persistence and recurrence of this kind of tumor are frequent. The analysis of prognostic factors shows the heterogeneity of these malignancies. In general survival is poor and treatment strategies are being discussed.

keywords:
Uterine sarcomas
Persistence
Recurrence
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.P. Forney, H.J. Buschbaum.
Classifying, staging, and treating uterine sarcomas.
Contemporary Ob/Gyn, 18 (1981),
[2.]
H. Page, A. Asire.
Cancer rates and risks, pp. 85-691
[3.]
F.J. Major, J.A. Blessing, S.G. Silverberg, C.P. Morrow, W.T. Creasman, J.L. Curie, et al.
Prognostic factors in early-stage uterine sarcoma: a gynecologic oncology group study.
Cancer, 71 (1993), pp. 1702-1709
[4.]
C.D. Arrastia, R.G. Fruchter, M. Clark, H. Maimam, J.C. Remy, M. Macasaet, et al.
Uterine carcinosarcomas: incidence and trends in management and survival.
Gynecol Oncol, 65 (1997), pp. 158-163
[5.]
A.H. Wolfson, D.S. Wolfson, S.Y. Sittler, L. Breton, A.M. Markoe, J.G. Schwade, et al.
A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas.
Gynecol Oncol, 52 (1994), pp. 56-62
[6.]
R. Nordal, S. Thorensen.
Uterine Sarcomas in Norway 1956-1992: incidence, survival and mortality.
Eur J Cancer, 33 (1997), pp. 907-911
[7.]
E. Asins, A. Herruzo, E. Armas, F. Ibáñez, J. Calero, S. Llixiona, et al.
Sarcomas uterinos.
Prog Obstet Ginecol, 43 (2000), pp. 207-215
[8.]
G.A. Omura, J.A. Blessing, F. Major, S. Lifshitz, C.E. Ehrlich, C. Mangan, et al.
A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.
J Clin Oncol, 3 (1985), pp. 1240-1245
[9.]
E. Hannigan, R. Freedman, F. Rutledje.
Adjuvant chemotherapy in early uterine sarcoma.
Gynecol Oncol, 15 (1983), pp. 56-64
[10.]
S. Nielsen, K. Podratz, V. Schalthavtr, P. O'Brian.
Clinico-pathologic analysis of uterine malignant mixed mullerian tumors.
Ginecol Oncol, 34 (1989), pp. 372-378
[11.]
N. Reed.
Uterine sarcomas.
The biggest challenge? Clin Oncol, 14 (2002), pp. 50-53
[12.]
P.S. Riddle, C.B. Echeta, S. Marrek, B.A. Lavery, F.M. Charnok, I. Mackenzie, et al.
Retrospective study of management of uterine sarcomas at Oxford 1990-1998: role of adjuvant treatment.
Clin Oncol, 14 (2002), pp. 54-61
[13.]
K.S. Olah, J.A. Dunn, H. Gee.
Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma.
Br J Obst Gynaecol, 99 (1992), pp. 590-594
[14.]
B. Bodner-Adler, K. Bodner, A. Obermair, K. Czerwenka, E. Petru, S. Leodolter, et al.
Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study.
Anticancer Res, 21 (2001), pp. 3069-3074
[15.]
P. Pautier, C. Genestie, A. Rey, P. Morice, B. Roche, C. Lhomme, et al.
Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
Cancer, 88 (2000), pp. 1425-1431
[16.]
P.G. Rose, M.S. Piver, Y. Tsukada, T. Lau.
Patterns of metastasis in uterine sarcoma. An autopsy study.
Cancer, 63 (1989), pp. 935-938
[17.]
S.S. Chen.
Propensity of retroperitoneal lymph node metastasis in patients with stage I sarcoma of the uterus.
Gynecol Oncol, 32 (1989), pp. 215-217
[18.]
W.M. Parker, Y.S. Fu, J.S. Berek.
Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.
Obstet Gynecol, 83 (1994), pp. 414-418
[19.]
M.S. Piver, S.B. Lele, D.L. Marchetti, L.J. Emrich.
Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas.
J Surg Oncol, 38 (1988), pp. 233-239
[20.]
L. Chauveinc, E. Deniaud, C. Plancher, X. Sastre, F. Amsani, A. De la Rochefordiere, et al.
Uterine sarcomas: the Curie Institut Experience. Prognosis factor and adjuvant treatments.
Gynecol Oncol, 72 (1999), pp. 232-237
Copyright © 2003. Sociedad Española de Ginecología y Obstetricia
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos